Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project.

ABSTRACT:

Background

A pandemic outbreak of COVID-19 has been sweeping the world since December. It begins as a respiratory infection that, mainly in men with diabetes or renal impairment, evolves into a systemic disease, with SARDS, progressive endothelial cell damage, abnormal clotting and impaired cardiovascular and liver function. Some clinical trials are testing biological drugs to limit the immune system dysregulation, "cytokines storm," that causes the systemic complications of COVID-19. The contraindications of these drugs and their cost raise concerns over the implications of their widespread availability.

Objectives

Numerous clinical and experimental studies have revealed a role for the nitric oxide (NO)-cyclic GMP-phosphodiesterase type 5 (PDE5) pathway in modulating low-gr

SUBMITTER: Isidori AM 

PROVIDER: S-EPMC7307129 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature